15 September 2020: Articles
Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases
Unusual or unexpected effect of treatment
Anthony Matta A* , Dorota Taraszkiewicz A , Vanina Bongard A , Jean Ferrières ADOI: 10.12659/AJCR.923722
Am J Case Rep 2020; 21:e923722
Table 1. Baseline LDL-C levels compared with LDL-C levels after starting PCSK9i and after adding a statin in the reported cases.
| Case | LDL-C Level Before Starting PCSK9i | LDL-C at 6–8 Weeks of PCSK9i | Change in LDL-C | LDL-C at 3 Months of Statin + PCSK9i | Change in LDL-C |
|---|---|---|---|---|---|
| 1 | 245 mg/dL | 290 mg/dL | +18% | 58 mg/dL | –76% |
| 2 | 419 mg/dL | 337 mg/dL | –20% | 158 mg/dL | –62% |
| LDL-C – low-density lipoprotein cholesterol; PCSK9i – proprotein convertase subtilisin/kinase 9 inhibitors. | |||||